Transcript Highlights:

• you know, COVID brought us into a new awareness of the risk and problems with blind trust in pharmaceutical
• manufacturer can be held responsible when their defective product harms someone, why not the pharmaceutical
• but for far too many that trust was betrayed, not by their neighbors or their doctors, but by pharmaceutical
• Why should pharmaceutical companies be any different?
• That's, that's the attempt anyway, that's so The federal law that Gave pharmaceuticals the the no liability

Bills: HB 220, HB 783, HB 2240, HB 3336, HB 4202, HB 4449, HB 4904, HB 3441, HB 4284

Keywords: sexual assault, healthcare facilities, forensic examination, survivor support, emergency contraceptive, online impersonation, civil liability, social media, identity theft, defamation, counseling damages, injunctive relief, public health, safety regulations, community health, state standards, healthcare access, HB 3336, alcoholic beverage tax credit, spent grain

Transcript Highlights:

• and pharmaceutical ingredients on the national security of the United States.
• In Proclamation 11020 of April 2nd, 2026, adjusting imports of pharmaceuticals and pharmaceutical ingredients
• I concur with the Secretary's findings that pharmaceuticals and associated pharmaceutical ingredients
• and pharmaceutical ingredients.
• and pharmaceutical ingredients, and the actions taken in the proclamation to eliminate that threat.

Keywords: U.S. House of Representatives Floor Proceedings on Monday, April 20, 2026, 1012, house, all

Transcript Highlights:

• I will tell you this administration has done significant work in the pharmaceutical arena.
• Number two: pharmaceuticals. Nearly 10% of hospital expenses are on pharmaceuticals.
• Number two: pharmaceuticals. Nearly 10% of hospital expenses are on pharmaceuticals.
• Members, this part of the panel is really focused on the pharmaceutical portion of costs.
• I'm with the Pharmaceutical Care Management Association.

Keywords: 1185, senate, all

Transcript Highlights:

• These are the three agencies that control pharmaceutical waste in Minnesota, and there are no compliance
• Man, I just had a question on what's the volume of dollars of pharmaceuticals that you have sent out
• So, uh, and you mentioned at the start $16 million of potential pharmaceuticals that go into the waste
• of pharmaceuticals that you have<00:15:51.199> sent<00:15:51.440> out<00:15:51.680>
• that go into potential pharmaceuticals that go into waste<00:16:09.360> stream.

Bills: HF3475, SF3832, HF3508, HF3917, HF3404, HF3593

Keywords: agriculture, education, leadership council, compensation, research institute, dairy assistance, investment relief, agriculture support, food production, economic relief, investment, relief initiative, farm support, medication repository, drug donation, healthcare, Minnesota Statutes, pharmacy, public health, controlled substances

Transcript Highlights:

• Purdue Pharmaceuticals are going to have billions of dollars in fines and settlements really coming up
• Purdue Pharmaceuticals,<00:04:49.520> Purdue<00:04:49.919> Pharmaceuticals Pharmaceuticals
• , Purdue Pharmaceuticals Pharmaceuticals, Purdue Pharmaceuticals are<00:04:50.880> going<00:04
• And what we have to do, members, is we have to have our claims bar released so that when pharmaceutical
• Pharmaceutical companies agree to give us the money that is owed to us so that we can get it to our communities

Keywords: 1183, house

Transcript Highlights:

• 00:35:27.599> Veterinary continuation of the Veterinary continuation of the Veterinary Pharmaceutical
• Advisory<00:35:29.200> Committee<00:35:29.359> and<00:35:29.599> in Pharmaceutical
• Advisory Committee and in Pharmaceutical Advisory Committee and in connection<00:35:30.000> therewith
• Regulatory Agencies to repeal the Regulatory Agencies to repeal the Veterinary<00:35:36.720> Pharmaceutical
• <00:35:37.359> Advisory Veterinary Pharmaceutical Advisory Veterinary Pharmaceutical Advisory

Keywords: 981, all

Transcript Highlights:

• I don't like pharmaceutical medicine. I use natural products as my medicine.
• I also know that even with pharmaceuticals, every person is different.
• Our bodies Know that even with pharmaceuticals, every person is different.
• And since then, I have suffered from the pharmaceutical industry.
• It freed me from the pharmaceutical chains I thought I'd be bound to forever.

Bills: SB 3, HB28, SB3

Keywords: flash flood, flood warning, outdoor warning siren, emergency alert, disaster preparedness, flood mitigation, Hill Country floods, Texas Water Development Board, municipalities, counties, local government mandate, public safety, grant program, backup power, weather siren, emergency management, flood-prone area, warning system, hemp regulation, consumable products

Transcript Highlights:

• Um, the impact of the pharmaceutical restrictions is not hypothetical.
• > impact of the pharmaceutical impact of the pharmaceutical restrictions<00:25:35.919> is<00:25
• <00:29:24.720> companies made by the pharmaceutical companies made by the pharmaceutical companies
• Goo or I don't pharmaceutical guys, Mr.
• concerns that the pharmaceutical concerns that the pharmaceutical companies<00:30:59.360> have

Keywords: 912, senate, all

Summary: The committee heard testimony on HB 302, which would expand access to medical cannabis by removing the in-person provider-patient relationship requirement and related restrictions. The Department of Health supported the bill, and multiple advocates and organizations testified in support, including the ACLU of Hawaii, Hawaii Alliance for Cannabis Reform, Marijuana Policy Project, and others. Supporters said the measure would improve access for patients, especially on outer islands, and some urged broader amendments allowing providers to certify cannabis for any medical condition and to speed registration and treat in-state and out-of-state patients equally. No opposition was heard, and the bill was left with no questions after testimony. The committee also heard HB 1052 HD1, which clarifies that the Public Utilities Commission may use universal service fund monies to provide free telecommunications access for individuals with print disabilities. Testimony was uniformly supportive from the DCCA Division of Consumer Advocacy, the State Council on Developmental Disabilities, the Department of Human Services, the Public Utilities Commission, and the National Federation of the Blind of Hawaii. Witnesses described the program as an important accessibility service that has been operating under prior appropriations and should continue under the universal service program. HB 1482, relating to controlled substances and hemp/synthetic cannabinoids, drew support from the Department of Law Enforcement, Department of Health, Honolulu Police Department, and others, with some comments from the Attorney General’s office. Supporters said the bill would clarify that delta-8 THC is a controlled substance and help enforcement against illegal hemp products and synthetic cannabinoids. Testimony and questioning focused on the need for better lab testing capacity, retail registry and age-gating, seizure authority, nuisance abatement, and possible use of special funds or appropriations to support enforcement. Members also discussed enforcement of illegal hemp businesses and whether additional funding or statutory changes would be needed. Finally, the committee took up HB 712, a 340B drug-discount measure affecting safety-net providers and contract pharmacies. Hospitals, health centers, and provider groups testified in support, saying the bill would protect access to discounted drugs and preserve funding for services such as chronic disease management, transportation, and specialty care. Pharmaceutical-industry representatives opposed the bill or sought amendments, arguing the 340B program has expanded beyond its original intent and lacks transparency, and they requested reporting or audit-like provisions to verify claims and revenues. Members questioned both sides about alleged abuse, the growth of contract pharmacies, and whether the bill should include transparency requirements before moving forward.

Transcript Highlights:

• The 340B program allows us to have discounted pharmaceuticals that are our folks would not be able to
• My name is Kyle, and I am the Director of State Policy for Pharmaceutical Research and Manufacturers
• Various different pharmaceutical companies that either limit the number of contract pharmacies.
• They're going to say, we're going to give you your pharmaceuticals.
• Our clinics absolutely cannot front enough money to cover pharmaceuticals on a refund program.

Transcript Highlights:

• Um very briefly our pharmaceutical work.
• that prohibits pharmaceutical that prohibits pharmaceutical manufacturers<01:03:36.000> from<
• the last two years with pharmaceutical the last two years with pharmaceutical manager<01:03:54.079
• It's more like pharmaceutical companies.
• > give<01:42:20.800> us<01:42:20.960> a pharmaceutical company to give us a pharmaceutical

Keywords: 919, house, all

Summary: The committee first approved the March 11, 2026 minutes, then heard House File 4048, which would exempt chiropractors from Minnesota’s provider tax if they are no longer eligible to provide chiropractic benefits under Medicaid/MinnesotaCare. Representative Robbins said the bill corrects an unfair situation because chiropractors still pay the tax even though the benefit was eliminated. Testifiers from the Minnesota Chiropractic Association and a longtime chiropractor supported the bill, arguing that most chiropractors are small-business owners and should not pay a tax for services they can no longer provide. Several members said they supported restoring chiropractic coverage instead of changing the tax, and there was discussion about whether the tax applies to all providers and whether it is effectively passed on to patients. The committee adopted a motion to recommend HF 4048 to the Committee on Taxes. The committee then took up House File 3893, as amended, a bill to restrict artificial intelligence from engaging in psychotherapy or counseling with humans. The author and supporters said the bill is intended to prevent AI chatbots from posing as therapists or counseling vulnerable people, citing reports of suicides and other harms linked to chatbot interactions. The A2 amendment was adopted; the author said it reflected stakeholder concerns and added informed-consent language. Testifiers in support, including a psychologist and a suicide-prevention nonprofit leader, urged strong safeguards and said AI should not replace licensed professionals in crisis settings. Other testimony raised concerns about overbreadth and unintended effects. TechNet and a rural mental health provider said the bill should be narrowed so it applies to clinical therapy rather than wellness or educational tools, and should allow supervised AI uses such as transcription and administrative support. Members discussed rural access, existing licensing-board authority, privacy laws, and whether the bill should target AI companies directly rather than licensed clinicians. The transcript ends during continued discussion of HF 3893, with no final committee action shown in the excerpt.

Transcript Highlights:

• Pharmaceutical companies should just simply lower their prices.
• rebates pharmaceutical companies should just<00:36:25.960> simply<00:36:26.240> lower<
• So what's happening today is that the pharmaceutical chain has become a rather perverted, convoluted
• with the pharmaceutical Care Management Association<00:54:14.319> otherwise<00:54:14.680>
• things are done at a pharmaceutic things are done at a pharmaceutic pharmacy<01:05:22.880> level

Keywords: 1187, senate, all

Transcript Highlights:

• The 4% increase the provider tax on pharmaceutical distributors.
• bands, you get into those old age bands and they're consuming a lot of those pharmaceuticals.
• bands, you get into those old age bands and they're consuming a lot of those pharmaceuticals.
• <01:15:15.120> companies wholesale pharmaceutical companies wholesale pharmaceutical companies
• so what we're really Pharmaceuticals so what we're really doing<01:16:36.120> is<01:16:36.280

Keywords: 1187, senate, all

Summary: The committee heard a reinsurance overview from Deputy Commissioner Julia Dryer of the Minnesota Department of Commerce on the Minnesota Premium Security Plan. She explained that reinsurance helps stabilize premiums in the individual market by reimbursing insurers for high-cost claims, and said Minnesota’s program has lowered premiums, preserved carrier participation, and helped maintain consumer choice. She warned that without continued funding, the program would be depleted and individual-market premiums could rise by about 25%, with potential losses in coverage and access to care. She also described the program’s structure under a federal 1332 waiver, the role of MCHA in administering the program, and the state’s receipt of more than $650 million in federal pass-through funds to date. Dryer said the current program is funded through the end of 2025, though the federal waiver authority runs through 2027. The governor’s proposal would create a new assessment on insurers, estimated at roughly 2% to 3%, to fund the state share of the program and avoid another full waiver submission. She noted that the proposal assumes MinnesotaCare funding would be held harmless and that the program would be reduced if federal basic health plan funding were negatively affected. She also said projected costs changed because individual-market enrollment has grown and enhanced federal subsidies were removed from the estimate. Members raised concerns about the proposal’s impact on premiums and the history of the fund. Senator Rasmusson argued the new assessment amounts to a large tax increase on health insurance and questioned who would be assessed and whether the surcharge would be capped. Dryer responded that the assessment would be based on annual claims experience and market conditions, with final amounts determined at the end of each year, not monthly. Senator Duckworth and Senator Frentz supported reinsurance as a way to keep premiums lower, while also questioning how the program should be financed. Senator Green asked about the mechanics of the assessment and the role of the department in setting it, and Senator H questioned why the fiscal note assumed 12% annual growth for program costs when general premium growth was lower. No vote or formal action was taken in the meeting.

Transcript Highlights:

• major 21st century manufacturing zones that we have had located for automotive industry-related, pharmaceuticals
• related, located for automotive industry related, located for automotive industry related, pharmaceuticals
• , pharmaceuticals, pharmaceuticals, uh uh uh semiconductor,<00:06:46.760> etc.

Bills: SB325, SB370

Keywords: AIDT, Alabama Industrial Development Training Institute, Department of Commerce, procurement, competitive bidding, contract review, legislative oversight, economic development, workforce development, Strategic Workforce Plan, state purchasing, state contracts, public procurement, exemption, higher education, universities, community colleges, public hospitals, health care procurement, transportation procurement

Transcript Highlights:

• And that is a that is a list of of of pharmaceuticals that pharmaceuticals that pharmaceuticals that
• . retail pharmaceuticals. retail pharmaceuticals.
• industry formulary, the pharmaceutical industry formulary, the pharmaceutical industry either has to
• That's the way it used to be before the pharmaceutical used to be before the pharmaceutical used to be
• before the pharmaceutical benefit managers came into benefit managers came into benefit managers came

Bills: SCR 13, SCR 24, SB 1, SB 12, SB 15, SB 17, SB 24, SB 57, SB 65, SB 213, SB 371, SB 372, SB 378, SB 379, SB 388, SB 400, SB 402, SB 427, SB 495, SB 499, SB 502, SB 509, SB 535, SB 583, SB 610, SB 621, SB 650, SB 706, SB 740, SB 840, SB 854, SB 856, SB 875, SB 893, SB 918, SB 925, SB 974, SB 995, SB 1006, SB 1018, SB 1025, SB 1061, SB 1073, SB 1106, SB 1121, SB 1194, SB 1252, SB 1253, SB 1268, SB 1300, SB 1343, SB 1362, SB 1447, SJR 36, SJR 12, SJR 57, SCR 25, SCR 22, SCR 12, SCR 24, SCR 8, SB 565, SB 372, SB 765, SB 62, SB 666, SB 707, SB 888, SB 687, SB 847, SB 1248, SB 740, SB 14, SB 1006, SB 504, SB 925, SB 1121, SB 995, SB 857, SB 305, SB 296, SB 284, SB 815, SB 1379, SB 1300, SB 1497, SB 1499, SB 1498, SB 1061, SB 65, SB 241, SB 304, SB 402, SB 499, SB 621, SB 974, SB 1023, SB 1024, SB 1025, SB 1106, SB 686, SB 112, SB 371, SB 204, SB 400, SB 609, SB 1447, SB 670, SB 502, SB 427, SB 850, SB 854, SB 413, SB 1555, SB 1362, SB 1346, SB 1033, SB 1220, SB 1073, SB 810, SB 987, SB 1539, SB 893, SB 447, SB 875, SB 406, SB 509, SB 985, SB 965, SB 1119, SB 1505, SB 24, SB 57, SB 1194, SB 1253, SB 1215, SB 1532, SB 1268, SB 1302, SB 856, SB 650, SB 583, SB 673, SB 840, SB 213, SB 681, SB 1172, SB 1252, SB 378, SB 610, SB 918, SB 1343, SB 608, SB 487, SB 955, SB 957, SB 988, SB 990, SB 1019, SB 1021, SB 1120, SB 251, SB 958, SB 535, SB 761, SB 1, SB 541, SB 315, SB 379, SB 1018, SB 1737, SB 266, SB 1415, SB 57, SB 499, SB 974, SB 1025, SB 1061, SB 1268, SR 302, SR 303, SR 304, SR 305, SB 30, SB 1333, SB 1666, SB 30, SB 1333, SB 1666

Keywords: water rights, treaty compliance, Rio Grande, agriculture, drought, international water, Texas water supply, Texas, Israel, trade, investment, partnership, economic ties, technological innovation, bilateral relations, appropriations, budget, state funding, education, healthcare

Transcript Highlights:

• In the health care space, we're trying to hold pharmaceutical companies accountable and reduce the cost
• > to<00:02:13.080> hold space, we're trying to hold space, we're trying to hold pharmaceutical
• <00:02:13.920> companies<00:02:14.520> accountable<00:02:15.280> and pharmaceutical
• companies accountable and pharmaceutical companies accountable and reduce<00:02:16.360> the<00

Keywords: 919, house, all

Summary: The discussion focused on the upcoming State of the State address and the DFL’s priorities for the remainder of the session. Jamie Long described the speech as a special event in the House chamber and said Minnesota is in good shape overall, crediting Governor Walz with steady leadership through recent challenges, including Operation Metro Surge, economic pressures, and calls for action on gun violence after the Annunciation shooting. Long said the caucus’s main focus is the cost of living, especially rising gas, food, housing, child care, and health care costs. He said the DFL is pursuing proposals to lower prescription drug prices, limit corporate homebuying, and reduce child care costs, and he emphasized that these issues have broad public support even if they face resistance in the Legislature. He said the caucus hopes to win bipartisan support for these measures. On the governor’s legacy, Long praised Walz as a strong partner to the Legislature and pointed to the 2023 and 2024 sessions as among the most impactful in state history. He cited accomplishments including investments in public schools, paid family and medical leave, 100% clean energy, and gun violence prevention, and said Walz can be proud of his eight years leading Minnesota.

Transcript Highlights:

• But unfortunately, in the last couple of years, there have been practices by some pharmaceutical companies
• actions, and following the lead of 21 states or 20-some-odd states, this bill would prohibit... ...pharmaceutical
• believe that this is something that we need to put in place because of the practices of certain pharmaceutical
• I believe that creating these limitations to what pharmaceutical companies, et cetera, can do would actually
• concerned, the reason why I believe this is necessary is precisely because the actions of some pharmaceutical

Keywords: 993, senate, all

Summary: The Health Committee met to consider a series of bills, many of them repeat proposals from prior sessions. Early measures included S.11 on disclosure for non-invasive prenatal screening, S.92 allowing redaction of certain physician names from birth certificates, S.135 creating practical support grants for abortion care, S.428A requiring chain restaurants to label high-sodium menu items, S.555 prohibiting visual images of people undergoing medical treatment without consent, and S.1614A establishing presumptive Medicaid eligibility for people leaving incarceration. The committee also advanced S.1438A to create an abortion clinical training program, S.1468 on access to medical records and limiting copy charges to actual cost, S.1619 expanding pharmacists’ authority to order and administer certain tests, and S.1714 banning the use of “excited delirium” as a diagnosis or cause of death. A substantial portion of the meeting focused on S.1633A, which would add protections for sensitive health information and allow patients to restrict disclosure of specified categories of data. One senator argued the bill could hinder care by limiting access to complete records, especially in emergencies, while supporters said the measure was needed to protect patients and providers from legal action by other states or the federal government, particularly in reproductive health cases. Staff clarified that the bill would allow segregation of specific sensitive data rather than locking an entire record. The committee also discussed S.1913, a 340B prescription drug anti-discrimination bill; supporters said it would protect safety-net providers and federally qualified health centers from pharmaceutical company practices, while one senator raised concerns about broad state intervention in a federal program. Additional bills advanced included S.5981 establishing a comprehensive sexual and reproductive health program, S.6178 directing a sickle cell disparity study, S.7457 permitting cremation or natural organic reduction for certain unclaimed decedents, S.7541 moving up reporting timelines for licensed home care services agencies, and S.8257A directing an alternative payment methodology for federally qualified health centers to support fertility care. Most bills were moved by committee vote, generally with some opposition or without recommendation, and were referred to first reading, rules, or finance as appropriate.

Transcript Highlights:

• We know these fluorocarbons and we know this material when you flush pharmaceuticals down the toilet
• Are you testing for these things, especially I'm interested in the PFOS and the pharmaceuticals?
• And also for pharmaceuticals and byproducts, or is that not currently being done? No, ma'am.
• Second of all, I think the Standards are weak from EPA on all the metals in the pharmaceuticals.
• As I mentioned previously, I have real concerns about the pharmaceutical products and their metabolites

Bills: HB3005, HB3007, HB3403, HB1907, HB3175, HB3986, HB3466, HB3411, HB4246

Keywords: climatology, emergency declaration, Oklahoma Climatological Survey, environment, weather data, public policy, state governance, natural resources, advisory councils, sunset law, water quality, hazardous waste, solid waste, radiation management, public health, biosolids, land application, environmental quality, agriculture, wastewater treatment

Transcript Highlights:

• benefit manager practices in the state to ensure transparency and fairness for consumers and in the pharmaceutical
• Thanks for being here. fairness for consumers and in fairness for consumers and in pharmaceutical<00:
• <00:18:15.679> lower<00:18:16.000> drug<00:18:16.400> costs pharmaceutical sectors
• . lower drug costs pharmaceutical sectors. lower drug costs for<00:18:17.120> patient<00:18:17.600
• My name is Tanya Neil, and I'm with the Pharmaceutical Care Management Trade Association.

Keywords: 910, house, all

Summary: The Committee on Health met on April 11, 2025, and heard testimony on a series of Senate concurrent and Senate resolution measures focused on health system oversight, workforce standards, and access to care. Topics included an auditor study on mandated insurance coverage for intravenous ketamine therapy for depression (SCR 8 SD1), a working group on prior authorization reform (STR 10 SD2), a task force on minimum professional standards for community health worker training (STR 16 SD1), a pharmacy benefit manager reform working group (SCR 69 SD1), a pharmacy reimbursement working group (STR 70 SD1), an aeromedical services working group (STR 86 SD1), a catchment-water feasibility study for business use (STR 118 SD1), an auditor study on mandatory coverage for continuous glucose monitors (STR 120 SD1), and a resolution encouraging reduced use of disposable surgical equipment and more sustainable health care practices (STR 194 SD1). Testimony was generally supportive across the measures, with several agencies and organizations noting the need to address complex health policy issues and improve access, transparency, and sustainability. For STR 16 SD1, community health worker advocates strongly supported the resolution but asked for amendments to include the Hawaii Community Health Worker Association on the task force and to require that at least half of the task force members be community health workers. For the PBM-related measures, SHPDA said it was willing to convene the work group and described the issue as complex, while the Pharmaceutical Care Management Association asked that PBMs be included in the working group. For STR 10 SD2, SHPDA supported the effort to reduce prior authorization burdens and said the process is a "black box" that needs reform; the chair later noted the administration’s commitment to the issue. For STR 86 SD1, the Department of Health supported the aeromed working group, and the chair proposed a House Draft 1 with technical changes and added representation from independent provider operators. In decision making, the committee adopted the chair’s recommendations on all measures considered. SCR 8 SD1 was passed as is. STR 10 SD2 was deferred. STR 16 SD1, STR 70 SD1, STR 118 SD1, STR 120 SD1, and STR 194 SD1 were passed as is. SCR 69 SD1 was passed with amendments, and STR 86 SD1 was passed with amendments. The meeting concluded with adjournment after all votes were taken.

Transcript Highlights:

• Committee will be meeting upon adjournment today to hear two sunset reviews, which are the Veterinary Pharmaceutical
• 23:14.960> Veterary reviews uh which are the Veterary reviews uh which are the Veterary Pharmaceutical
• <00:23:16.159> Advisory<00:23:16.720> Committee<00:23:17.200> and Pharmaceutical
• Advisory Committee and Pharmaceutical Advisory Committee and the<00:23:17.919> Forest<00:23:18.400

Keywords: 981, all

Transcript Highlights:

• The pharmaceutical cocktails.
• I don't like pharmaceutical medicine.
• I also know that, even with pharmaceuticals, every person is different.
• And since then, I I have suffered from the pharmaceutical industry. I had the capacity.
• It freed me from the pharmaceutical chains I thought I'd be bound to. forever.

Bills: HB 28, SB 3

Keywords: hemp regulation, consumable products, cannabinoids, state health, youth protection, licensing fees, criminal offenses, HB28, public testimony, committee decorum, bill substitute, legislative process

Summary: The meeting featured significant discussions regarding HB28, where the chair outlined the plans to bring forward a substitute for the bill. The chair emphasized the importance of maintaining order and decorum during the proceedings. Members engaged in deliberations, and a number of public witnesses were invited to testify, thereby enriching the discussion around the bill. This interaction provided valuable insights into public sentiment regarding the issues at hand.